These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26894485)

  • 1. Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim.
    Moukharskaya J; Abrams DM; Ashikaga T; Khan F; Schwartz J; Wilson K; Verschraegen C; Openshaw T; Valentine J; Eneman J; Unger P; Ades S
    Support Care Cancer; 2016 Jul; 24(7):3085-93. PubMed ID: 26894485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.
    Kirshner JJ; McDonald MC; Kruter F; Guinigundo AS; Vanni L; Maxwell CL; Reiner M; Upchurch TE; Garcia J; Morrow PK
    Support Care Cancer; 2018 Apr; 26(4):1323-1334. PubMed ID: 29147854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe pegfilgrastim-induced bone pain completely alleviated with loratadine: A case report.
    Romeo C; Li Q; Copeland L
    J Oncol Pharm Pract; 2015 Aug; 21(4):301-4. PubMed ID: 24664474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When Hydromorphone Is Not Working, Try Loratadine: An Emergency Department Case of Loratadine as Abortive Therapy for Severe Pegfilgrastim-Induced Bone Pain.
    Moore K; Haroz R
    J Emerg Med; 2017 Feb; 52(2):e29-e31. PubMed ID: 27751704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade.
    Gavioli E; Abrams M
    Support Care Cancer; 2017 Mar; 25(3):817-822. PubMed ID: 27817104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients.
    Pawloski PA; Larsen M; Thoresen A; Giordana MD
    J Oncol Pharm Pract; 2016 Jun; 22(3):423-9. PubMed ID: 25956422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Loratadine for Pegfilgrastim-Induced Bone Pain.
    Mazzola J; Hennon P; Peine K; Siedlecki SL
    Pain Manag Nurs; 2024 Apr; 25(2):e132-e137. PubMed ID: 38216368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management.
    Moore DC; Pellegrino AE
    Ann Pharmacother; 2017 Sep; 51(9):797-803. PubMed ID: 28423916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.
    Leung M; Florendo J; Kano J; Marr-Del Monte T; Higgins B; Myers R; Menon T; Jones G
    Support Care Cancer; 2015 Jun; 23(6):1669-77. PubMed ID: 25421443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
    Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
    Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral loratadine in the management of G-CSF-induced bone pain: a pilot study.
    Duggan C; Murphy L; Costello V; Leary EO; Yousif AD; Blazkova S; Dowling M
    Br J Nurs; 2019 Feb; 28(4):S4-S11. PubMed ID: 30811242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base.
    Kirshner JJ; Heckler CE; Janelsins MC; Dakhil SR; Hopkins JO; Coles C; Morrow GR
    J Clin Oncol; 2012 Jun; 30(16):1974-9. PubMed ID: 22508813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can loratadine help in treating granulocyte-colony stimulating factor-induced bone pain?
    Gajarawala SN; Pelkowski JN; DeStephano CC
    JAAPA; 2021 Jul; 34(7):29-31. PubMed ID: 34162806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim.
    Xu H; Gong Q; Vogl FD; Reiner M; Page JH
    Support Care Cancer; 2016 Feb; 24(2):723-730. PubMed ID: 26162536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial.
    Lambertini M; Bruzzi P; Poggio F; Pastorino S; Gardin G; Clavarezza M; Bighin C; Pronzato P; Del Mastro L
    Support Care Cancer; 2016 Mar; 24(3):1285-94. PubMed ID: 26306520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegfilgrastim.
    Curran MP; Goa KL
    Drugs; 2002; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
    J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
    Lee KH; Kim JY; Lee MH; Han HS; Lim JH; Park KU; Park IH; Cho EK; Yoon SY; Kim JH; Choi IS; Park JH; Choi YJ; Kim HJ; Jung KH; Kim SY; Oh DY; Im SA
    Support Care Cancer; 2016 Apr; 24(4):1709-17. PubMed ID: 26423618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine.
    Berger WE; White MV;
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):205-11. PubMed ID: 12952117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.